Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $50 to $32.

July 23, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on 10x Genomics (TXG) but lowers the price target from $50 to $32.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100